Stock Taper
SCREENER COMPARE ANY 2 STOCKS
LTGO
LATIGO BIOTHERAPEUTICS INC.
NASDAQ
$22.37
▲ UP 4.53% (0.97)

KEY STATISTICS

Market Cap$1.35 B
52w High$22.90
52w Low$17.22
Dividend Yield—
Frequency—
P/E—
Volume197.20K
Shares Out.60.15M

COMPANY

LEADERSHIP

Nima Farzan
CHIEF EXECUTIVE
Nima Farzan

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 7, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
59

PRICE

$22.37 ▲ UP 4.53% (+$0.97)
$21.20$21.60$22.00$22.409:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM22.37

About Latigo Biotherapeutics Inc.

http://www.latigobio.com ↗

Latigo Biotherapeutics, founded in 2018 in Thousand Oaks, CA, is a clinical-stage biopharma developing non-opioid pain medicines like LTG-001 and LTG-418 to quickly and effectively block pain transmission without addiction risk.

INDUSTRY

Medical - Pharmaceuticals

A PRODUCT LATIGO BIOTHERAPEUTICS INC. IS KNOWN FOR

LTG-001
LTG-001

LTG-001, Latigo Biotherapeutics' lead Phase 3 oral non-opioid medication, targets moderate to severe acute pain, offering effective relief without addiction.

INSIDER TRADES

★
10 PERCENT OWNER
5AM Ventures VI, L.P.
Purchase · 2.4M shares
2026-08-10
★
10 PERCENT OWNER
Sanofi
Purchase · 494.8K shares
2026-08-10
★
10 PERCENT OWNER
Sanofi
Sale · 494.8K shares
2026-08-10
★
10 PERCENT OWNER
Sanofi
Sale · 178.0K shares
2026-08-10